Company intelligence / Profile preview

OptiGen

Horsham, South of England, United Kingdom

Ownership: Private
Development stage: Other

Overview

OptiGene has developed commercial molecular diagnostics instruments including the Genie II (flagship product in full production since spring 2011) and Genie HT (high-throughput variant) that enable rapid, point-of-care detection of DNA and RNA with results in minutes rather than hours

Therapeutic areas: OtherInfectious Diseases
Modalities: Isothermal amplification-based detection assays
Industry: Molecular Diagnostics

Partnerships

Growing network of international distributorsOEM customization services available

Beyond the preview

Go deeper on OptiGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OptiGen.

Explore the full profile